4D Pharma Plc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From 4D Pharma Plc
EcoR1 and Casdin/Corvex took their second and third special purpose acquisition corporations public. Also, Ionis sold notes to buy back older notes and fund operations as it cut 70% of Akcea’s staff. In venture capital, ValenzaBio raised $70m and RA boosted Metagenomi’s series A to $75m.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
After years of halting progress in its microbiome-based pipeline, 4D Pharma has produced promising early data from its cancer immunotherapy combination.
Coronavirus Notebook: New Therapeutic Approaches, Fair Access To Dexamethasone, & Patent Help From The EPO
With COVID-19 cases about to top 12 million worldwide, efforts are continuing to identify the most promising drug candidates and to ensure that the rising star dexamethasone is made available to all.